Zogenix (ZGNX) : 22 days before expiry, shorts in Zogenix (ZGNX) have reduced from 3,461,858 on Jul 29, 2016, to 3,356,749 on August 15, 2016. On an average, 155,933 shares are traded on the exchange. The outstanding bearish positions are equal to 13.7% of the float. Short sellers have covered -105,109 shares, a reduction of -3%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Zogenix (NASDAQ:ZGNX): The stock opened at $9.53 on Wednesday but the bulls could not build on the opening and the stock topped out at $9.70 for the day. The stock traded down to $8.76 during the day, due to lack of any buying support eventually closed down at $8.88 with a loss of -7.11% for the day. The stock had closed at $9.56 on the previous day. The total traded volume was 116,278 shares.
In a related news, Hawley Roger, director of Zogenix, Inc., had purchased 10,000 shares on December 15, 2015. The total value of the transaction was $137,400. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Zogenix, Inc. (Zogenix) is a pharmaceutical company, which is engaged in development and commercialization of therapies for people with central nervous system (CNS) disorders. The Company focuses on the areas of pain, epilepsy and schizophrenia. It is engaged in the development of Relday, a product candidate for the treatment of schizophrenia. The Company develops ZX007, an abuse-deterrent tablet formulation of single entity, extended-release hydrocodone. The Company commercializes Sumavel DosePro (sumatriptan injection), a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache. The Company sells Sumavel DosePro to wholesale pharmaceutical distributors, pharmacies and hospitals.